These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33116490)

  • 1. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
    Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabrication of Ibrutinib Nanosuspension by Quality by Design  Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
    Rangaraj N; Pailla SR; Chowta P; Sampathi S
    AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation.
    Chang D; Ma Y; Cao G; Wang J; Zhang X; Feng J; Wang W
    Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1018-1024. PubMed ID: 28749189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible eprosartan mesylate nanopowder.
    Shekhawat P; Bagul M; Edwankar D; Pokharkar V
    Eur J Pharm Sci; 2019 Apr; 132():72-85. PubMed ID: 30797937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
    Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
    Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploitation of nanocrystal suspension as an effective oral formulation for oxfendazole.
    Sun Y; Chen D; Zhao Y; Zhou K; Zhang B; Wang H; Xie S
    Drug Deliv Transl Res; 2022 May; 12(5):1219-1229. PubMed ID: 34148210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA; ElMeshad AN; Fares AR
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
    Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
    Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
    Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
    Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryo-TEM and AFM Observation of the Time-Dependent Evolution of Amorphous Probucol Nanoparticles Formed by the Aqueous Dispersion of Ternary Solid Dispersions.
    Zhao Z; Katai H; Higashi K; Ueda K; Kawakami K; Moribe K
    Mol Pharm; 2019 May; 16(5):2184-2198. PubMed ID: 30925218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
    Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability.
    Khan MA; Ansari MM; Arif ST; Raza A; Choi HI; Lim CW; Noh HY; Noh JS; Akram S; Nawaz HA; Ammad M; Alamro AA; Alghamdi AA; Kim JK; Zeb A
    Drug Deliv; 2021 Dec; 28(1):2510-2524. PubMed ID: 34842018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.